New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
ApexOnco Front Page
Recent articles
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
Bicara and DualityBio will soon test market appetite for new oncology issues.
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.